Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04802733 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
A Phase 1 study of Advanced Parkinson's Disease, sponsored by BlueRock Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT04802733: Completed Phase 1 study of Advanced Parkinson's Disease, sponsored by BlueRock Therapeutics.
NCT04802733 is a Phase 1 study of Advanced Parkinson's Disease that has completed, run by BlueRock Therapeutics. The registered enrollment target is 12 participants, below the 130-participant average among 3 other Advanced Parkinson's Disease trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04802733, a Phase 1 study of Advanced Parkinson's Disease, has completed, sponsored by BlueRock Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
Primary Outcome
The incidence of Serious Adverse Events (SAEs) at 1 year post-transplant. or abnormal tissue overgrowth related to presence of transplanted cells;
Conditions Studied
Interventions
- BIOLOGICAL MSK-DA01
- DEVICE MSK-DA01 Cell Delivery Device
Study Locations (3)
California
- University of California Irvine - Orange
New York
- Weill Cornell Medical College - New York
Ontario
- Toronto Western Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 1 |
What the finished NCT04802733 record still lists
NCT04802733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 130-participant average among 3 other Advanced Parkinson's Disease trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Advanced Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which MSK-DA01 is the first listed.
NCT04802733 reports a single indexed study location in California, New York, Ontario.
Frequently Asked Questions
What is clinical trial NCT04802733 about?
NCT04802733 is a clinical study titled "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease". This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
What is the current status of trial NCT04802733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-03. Estimated completion is 2024-06-10.
What conditions does trial NCT04802733 study?
This clinical trial studies the following conditions: Advanced Parkinson's Disease.
What interventions are being tested in trial NCT04802733?
The interventions under investigation include: MSK-DA01 (BIOLOGICAL), MSK-DA01 Cell Delivery Device (DEVICE).
Who is sponsoring clinical trial NCT04802733?
This trial is sponsored by BlueRock Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04802733 being conducted?
This trial has 3 study locations across California, New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
RECRUITING · Phase 1
-
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
COMPLETED · Phase 3
-
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI